Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Dry Age Related Macular Degeneration (AMD) Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The market for dry age-related macular degeneration (AMD) has experienced robust expansion lately, projected to increase from $4.89 billion in 2025 to $5.32 billion in 2026, reflecting a compound annual growth rate of 8.8%. Factors contributing to this growth during the past period include the increasing elderly demographic, the proliferation of ophthalmology clinics, the wider acceptance of vitamin therapies, progress in retinal imaging technology, and heightened public consciousness regarding vision impairment.
The market for dry age-related macular degeneration (AMD) is poised for considerable expansion over the coming years, with projections indicating a valuation of $7.36 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth throughout the forecast period is largely attributable to advancements in novel therapeutic pipelines, the burgeoning field of precision ophthalmology, the integration of AI in retinal diagnostics, the implementation of preventative eye care initiatives, and substantial investments in clinical trials. Key developments shaping this market in the coming years encompass an intensified emphasis on early diagnosis of the condition, a greater reliance on nutritional supplement interventions, expanded research into drugs capable of modifying disease progression, increased utilization of sophisticated retinal imaging technologies, and heightened patient awareness coupled with more widespread screening efforts.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21176&type=smp
Dry Age Related Macular Degeneration (AMD) Market Growth Factors Supporting Long-Term Expansion
The escalating number of elderly individuals globally is poised to be a significant catalyst for the expansion of the dry age-related macular degeneration (AMD) market. This demographic, encompassing those aged 65 and above, experiences natural aging processes that heighten their demand for medical attention and specialized eye care. Factors such as extended lifespans, enhanced control over persistent illnesses, progress in healthcare innovations, and wider availability of elder care services are contributing to this demographic shift. The dry AMD market plays a crucial role by providing specific treatments and care strategies designed to mitigate retinal deterioration and safeguard vision in this age group. A notable indicator of this trend is the United Nations’ report from July 2023, which indicated that the global population aged 65 and older stood at 0.77 billion in 2022 and is anticipated to reach approximately 1.0 billion by the year 2030. Consequently, the increasing prevalence of the elderly population is a key driver fueling the advancement of the dry age-related macular degeneration (AMD) market.
Dry Age Related Macular Degeneration (AMD) Market Segment Breakdown: Which Categories Generate The Most Revenue?
The dry age related macular degeneration (amd) market covered in this report is segmented –
1) By Stages: Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years, Above 60 Years, Above 40 Years
3) By Route Of Administration: Oral, Injectables
4) By End Users: Hospitals And Clinics, Diagnostic Centers, Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation, Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits, Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy, Central Vision Loss
Dry Age Related Macular Degeneration (AMD) Market Industry Trends Shaping Future Revenue Growth
The primary players within the dry age-related macular degeneration (AMD) market are concentrating their efforts on pioneering innovative technological solutions, including light delivery systems, aimed at stimulating retinal cells, enhancing visual acuity, and potentially mitigating the advancement of the disease. These light delivery systems encompass therapeutic apparatuses engineered to administer specific light wavelengths to designated areas of retinal tissue, thereby promoting cellular activity and bolstering retinal well-being through the application of non-invasive photobiomodulation methods. A notable development occurred in January 2024 when LumiThera Inc., a medical device enterprise headquartered in the United States, introduced its photobiomodulation therapy for dry AMD, incorporating the Valeda Light Delivery System, which holds the distinction of being the inaugural FDA-authorized intervention for vision impairment linked to dry AMD. This sophisticated system employs a multi-wavelength light delivery strategy, utilizing wavelengths of 590 nm, 660 nm, and 850 nm to foster retinal cell stimulation, and LumiThera concurrently commenced the EUROLIGHT registry study to gather comprehensive long-term outcome information, with the treatment regimen generally comprising nine sessions spread across a three- to four-week timeframe.
Dry Age Related Macular Degeneration (AMD) Market Key Players And Strategic Industry Positioning
Major companies operating in the dry age related macular degeneration (amd) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Apellis Pharmaceuticals Inc., Belite Bio Inc., Alkeus Pharmaceuticals Inc., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc., Regeneron Pharmaceuticals Inc., Annexon Biosciences Inc., Stealth BioTherapeutics Corp., Kodiak Sciences Inc., Ionis Pharmaceuticals Inc., Lineage Cell Therapeutics Inc., Ocular Therapeutix Inc.
Access The Complete Dry Age Related Macular Degeneration (AMD) Market Report:
Dry Age Related Macular Degeneration (AMD) Market Geographic Analysis: Where Is Demand Growing The Fastest?
North Americawas the largest region in the dry age-related macular degeneration (AMD) market in 2025. The regions covered in the dry age related macular degeneration (amd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
